Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VE 303

Drug Profile

VE 303

Alternative Names: VE-303

Latest Information Update: 30 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vedanta Biosciences
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Bacteria
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium difficile infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Clostridium difficile infections; Hepatic encephalopathy

Most Recent Events

  • 28 Nov 2023 Vedanta Biosciences has patent protection for cover compositions of clostridia bacterial species in European Union
  • 10 Nov 2023 Efficacy, adverse event and pharmacokinetics data from phase II trial in Hepatic encephalopathy presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 08 May 2023 Vedanta Biosciences plans a pivotal phase III RestoratiVE303 trial for Clostridium difficile infections (Recurrent, Prevention) in the coming months
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top